Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced positive top-line data from the Phase 3 CAHtalyst Pediatric Study evaluating the efficacy, safety, and tolerability of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Crinecerfont is an oral, selective corticotropin-releasing factor type 1 receptor antagonist being investigated to help reduce and control excess adrenal androgens through a steroid-independent mechanism.
October 05, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences' positive Phase 3 study results for crinecerfont could potentially lead to regulatory approval and a new revenue stream for the company.
Positive Phase 3 trial results are a significant milestone in drug development, often leading to regulatory approval and commercialization. This could potentially open a new revenue stream for Neurocrine Biosciences, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100